

Article Type: Review

Title: Informatics for Cancer Immunotherapy

Authors: J. Hammerbacher¹, A. Snyder²

Affiliations:

¹Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029;

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425

²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065; Department of Medicine,

Weill Cornell Medical College, New York, NY 10065

Correspondence: correspondence@hammerlab.org


Abstract: The rapid development of immunomodulatory cancer therapies has led to a concurrent increase in the application of informatics techniques to the analysis of tumors, the tumor microenvironment, and measures of systemic immunity. In this review, the use of tumors to gather genetic and expression data will first be explored. Next, techniques to assess tumor immunity are reviewed, including HLA status, predicted neoantigens, immune microenvironment deconvolution and T-cell receptor (TCR) sequencing. Attempts to integrate these data are in early stages of development and are discussed next. Finally, we review the application of these informatics strategies to therapy development, with a focus on vaccines, adoptive cell transfer, and checkpoint blockade therapies.

Key words: computational biology, bioinformatics, immunotherapy, neoantigens, checkpoint blockade, adoptive cell transfer

Introduction

The quest to understand and improve how the immune system identifies and eradicates cancer can make use of data from dozens of molecular, cellular, and tissue profiling technologies. The primary focus of this review will be bioinformatic analyses of data generated by high-throughput DNA and RNA sequencing of bulk normal and tumor cell populations.

First, computational tools that consider cancer and the immune system separately will be discussed, followed by a discussion of how to better understand the interaction of the immune system and cancer. Finally, methods to dissect therapeutic responses to interventions such as vaccination, checkpoint blockade, and adoptive cell transfer will be reviewed.



Cancer informatics

Cancer is a disease of the genome [1], so it is common to profile the mutations and transcripts present in both the patient's peripheral blood or nearby normal tissue and one or more tumor samples [2]. A summary of common uses of this data in cancer research follows; for a more detailed review see [3].


Sample heterogeneity

The proportion of tumor cells in a cancer tissue sample is known as the “cellularity” or “purity” of the sample. Cellularity is an important metric for any type of downstream analysis since it is directly associated with the intensity of the tumor signal in genomic data. Inferring cellularity is complicated in some cancers because of challenges involved with pathologically excising normal tissue; in addition, nearby cells that appear normal microscopically often harbor somatic mutations similar to those found in cancer cells [4]. ABSOLUTE [5] and ESTIMATE [6] are two commonly-used tools to compute cellularity from sequencing data; recent work compared these tools to each other and to pathology-based estimates of cellularity and found low, but positive, correlation between sequence-based and pathology-based estimates [7]. While ESTIMATE uses gene expression as input, ABSOLUTE uses somatic copy number to quantify cellularity and hence is sensitive to errors in copy number estimates.

Within the population of tumor cells there is heterogeneity [8, 9]. Tumor cells can be partitioned into clonal families, and it is sometimes possible to reconstruct the phylogeny of tumor cells to better understand the spatial and temporal evolution of tumor heterogeneity [10–14]. Tools like THetA [15], PyClone [16], SciClone [17], PhyloWGS [18], QuantumClone [19], and Canopy [20]

have been developed to compute tumor phylogenies, and visualization tools like BubbleTree [21] and fishplot [22] can be useful to better comprehend tumor evolution [23]. These tools operate on genomic data obtained from either a single tumor sample (THetA, PyClone, SciClone, Canopy, bubbletree) or multiple samples (QuantumClone, fishplot) that are spatially or temporally distinct from each other.

Recently, single-cell sequencing technologies have been employed to improve sample heterogeneity estimates [24–26]; these approaches are reviewed in [27].



Somatic mutation calling

The Genomic Data Commons [28] makes available single nucleotide variant and short insertion and deletion (indel) calls from MuTect2, SomaticSniper [29], VarScan2 [30], and MuSE [31]. A recent ICGC benchmarking exercise [32] made use of two additional callers, MuTect [33] and Strelka [34]. In practice, it is common to combine the results of several somatic mutation callers to produce a consensus list of high-confidence calls [35, 36].

While simple mutations are the most frequent form of genomic alteration in cancer cells, more complex mutations are almost always present and are often oncogenic drivers. Complex mutations can be organized into categories [37], and it is common to use a different tool for each category of complex mutation.

Software for structural variant detection includes DELLY [38], Meerkat [39], and novoBreak [40]. It is helpful to have whole genome DNA-seq data when using these tools, since these variations often affect large chromosomal regions, and are difficult to detect with whole exome DNA-seq data.

Two recent benchmarks [41, 42] of gene fusion detection software found that EricScript [43], SOAPfuse [44], FusionCatcher [45], and JAFFA [46] performed well. These tools make use of RNA-seq data as input.

Somatic copy number alterations (SCNAs) for the TCGA project were estimated with ABSOLUTE [47]. Recent benchmarks [48, 49] of software for SCNA calling from sequencing data highlighted ADTE_x [50] and EXCAVATOR [51] as top performers. Tools not included in those benchmarks that may be useful include seqCNA [52], Sequenza [53], hapLOHseq [54], and CNVkit [55].

Challenges to the field of bioinformatics include the need for continuous updates to these programs, and the conflict between repeated benchmarking to delineate the best program versus consistent use of the same program to compare results between studies.

The somatic mutation callers discussed above make assumptions about sequencing protocols and read preprocessing software and methods. For example, many simple mutation detection methods expect whole exome data, and the choice of the exome capture kit can alter the somatic mutations identified. Sequencing depth is a critical consideration for detecting somatic mutations, as higher depth can better resolve sample heterogeneity issues. Usually one normal and one tumor genome are sequenced; however, some somatic mutation callers try to infer somatic mutations without a normal sample [56], while others can make use of RNA-seq data [57, 58] or data from DNA-seq of multiple samples. Biopsy and tissue preservation methods can also impact somatic mutations detected [59, 60].

Standard read preprocessing includes alignment to the human reference, base quality score recalibration, duplicate removal, and realignment of indels [61]. It is also important to profile the quality of the sequencing data and the alignments [62]. Significant coordination of many software tools is required to implement quality control, alignment, post-alignment processing, and both simple and complex mutation calling [63]. Most labs still manually examine somatic mutation calls with tools like IGV [64] or pileup.js [65] to confirm their accuracy, as in [32]. Whole pipelines have been published that can serve as a model for investigators setting up their own computational programs [66–68]. As of 2017, there is no consensus on the most sensitive and specific pipeline.

In fact, despite years of work on somatic mutation calling, it is still common for two labs to produce highly discordant results on the same input material, even for simple mutations called from targeted panels [69] or whole exome sequencing [70]. Attempts to benchmark somatic

mutation calling pipelines often consider only concordance comparisons [71] or validate on simulated data [72], and the most commonly used validation technique, Sanger sequencing, is time consuming and not always accurate [73]. Recently, in an effort to address this quandary and provide model data, high-coverage whole genome, whole exome, and targeted panel data have been made available for a single AML case [74]. While this high coverage data will be useful, it still does not capture the significant impact of variation in sequencing protocols across sites [75].

Sample heterogeneity further complicates the validation process. Ultimately, a standards body should provide isogenic cell lines that can allow for benchmarking of a site's somatic mutation calling process, similar to Genome in a Bottle for germline mutation calling [76].

Annotation

After enumerating high-confidence somatic mutations in a tumor sample, the next step is to annotate each mutation with its expected impact. Basic annotations include whether the mutation occurs within a gene, whether it alters the protein produced from that gene, and the specific amino acid alterations expected. Cancer-related annotations include whether the mutation occurs within a “driver” gene [57] that is known to contribute to the progression of cancer and whether a drug exists that can target cells carrying the mutation.

Common tools for the annotation of somatic mutations include VEP [77], SnpEff [78], ANNOVAR [79, 80], and Oncotator [81]. These tools make use of databases like ENSEMBL [82, 83], RefSeq [84], and the UCSC Known Genes database [85] for basic annotations, and COSMIC [86], CIViC [87], and PMKB [88] for cancer-related annotations. The calling and annotation of somatic mutations is reviewed in [89]. It is important to note that there are differences among the annotation databases that can impact downstream analyses [90–92].

Mutational signatures

Researchers recently disaggregated the biological processes generating somatic mutations in cancer by examining the trinucleotide context of somatic mutations in thousands of tumor samples [93]. These mutagenic processes include disruptions to the DNA damage repair pathway [94], environmental insults like smoking [95] and UV radiation, and chemotherapy [96]. Tools like deconstructSigs [97] facilitate the determination of the mutagenic processes present in a single tumor sample. Lessons from several years of mutational signature detection were recently distilled in a review [98].

Molecular subtypes

In addition to the intra-tumor heterogeneity discussed above, tumors also vary across individuals [99] and can be categorized in a variety of ways, including clinically (e.g., by organ and stage) and pathologically (e.g., by grade and cell morphology). DNA-seq and RNA-seq data, the focus of this review, can also be used to categorize cancers into subtypes [100]. It is

common to start with a single cancer, as categorized by organ or tissue of origin, and identify molecular subtypes using DNA-seq, RNA-seq, and other forms of sequencing data. Many of the TCGA research network publications attempt to identify molecular subtypes of a specific cancer in this way, for example in the cases of head and neck squamous cell [101] and clear cell renal cell [102] carcinomas. Another approach is to look for molecular subtypes across a variety of cancers [103].

Pathway analysis

Systems biologists have mapped the hallmarks of cancer [104] and other cell behaviors onto the underlying protein-protein interaction and transcriptional regulatory networks that implement the behaviors [105–107]. These gene sets or pathways are collected in databases like KEGG [108, 109], GeneSetDB [110], MSigDB [111], and Reactome [112].

Grouping altered genes according to these gene sets and pathways increases the statistical power of computational analyses and also permits a higher-level view of altered cellular mechanisms based on our prior information on genes' roles. Tools like Gene Set Enrichment Analysis (GSEA) [113, 114] and Ensemble of Gene Set Enrichment Analyses (EGSEA) [115] leverage gene sets for a better comparison of two groups of samples. This type of analysis is commonly used when comparing normal samples to tumors, tumors to a panel of normal samples (when the matched normal sample is not available) [116], or two sets of tumor samples that have different phenotypes (such as responders and non-responders). When a more granular understanding of the altered pathways for individual samples is needed, it is more common to use tools like single sample GSEA (ssGSEA) [117], gene set variation analysis (GSVA) [118], and moGSA [119] that perform single-sample gene set or pathway enrichment analysis.


Immunoinformatics

As immune modulatory agents join the armamentarium of anti-cancer therapies, bioinformaticians involved in translational studies are increasingly using tools that profile the state of the immune system, both local and systemic.

HLA typing

While the immune system has many cell types, the primary effector cells of tumor immunity are T cells [120]. T cells are activated in part by major histocompatibility complex (MHC) proteins presenting peptides for inspection on the surface of target cells [121]. In humans, the MHC genes are known as human leukocyte antigens (HLA), and they vary widely across individuals. There are three Class I and three Class II HLA genes, with the former recognized by CD8+ T cells and the latter by CD4+ T cells [122]. Enumerating the 12 alleles of these genes present in an individual is known as HLA typing. Most HLA typing methods make use of a database of known HLA alleles that is maintained by International ImMunoGeneTics (IMGT) [123].

High-resolution HLA typing can now be performed with DNA or RNA sequencing rather than serology [124]. Software for HLA typing includes ATHLATES [125] and POLYSOLVER [126], which take whole exome DNA-seq data; seq2HLA [127], which works with RNA-seq data; and OptiType [128], which works with either DNA-seq or RNA-seq data. A recent benchmark of seven algorithms found OptiType to be the most accurate on whole exome DNA-seq data for Class I HLA typing [129]. Promising new directions for HLA typing include using long read DNA-seq [130–132] and representing the polymorphic HLA region as a graph [133].



Epitope prediction

The antigen processing machinery (APM) of a cell is responsible for sampling proteins and peptides from the cell interior for display to T cells [134]. If a presented peptide generates a T cell response, it is referred to as an epitope and said to be immunogenic.

There are many stages in the Class I APM pathway that can be predicted, including proteasomal cleavage, MHC binding, and presentation. The Immune Epitope Database (IEDB) [135] has curated measurements of each stage. Using IEDB data as input, researchers have built comprehensive predictors of how the Class I APM pathway will process a protein [136]. The most critical value to predict as a proxy for immunogenicity appears to be the binding affinity of peptide to the MHC protein [137]. Predictors for p/MHC binding affinity have been progressively improving for decades, led by the NetMHC family of predictors, accounting for

complexities such as HLA alleles with little or no training data [138], variable peptide lengths [139], and variable binding affinity distributions across HLA alleles [140]. Other top performing predictors on the IEDB MHC Class I benchmark [141] include SMMPMBEC [142], MHCflurry [143], and the IEDB Consensus predictor [144].

Class II epitope prediction is currently far more difficult than Class I because the Class II APM pathway is complex [145], and Class II epitopes have more variable lengths and binding positions. For a recent review of Class I and Class II epitope prediction software, see [146].

Recently, advances in mass spectrometry have allowed direct and high-throughput measurement of presented peptides [147–150], so it is likely that presentation will soon replace MHC binding affinity as the most common outcome to predict as a proxy for immunogenicity. Beyond presentation, high-throughput measurements of TCR interactions with pMHC complexes are in development [151, 152]. It may one day be possible to predict pMHC/TCR interactions rather than p/MHC binding or pMHC presentation.

Predicting epitopes is complicated by our incomplete understanding of the origin of the peptides presented by a cell [153]. Some have suggested that defective ribosomal products (DRiPs) account for a significant fraction of presented peptides [154]; others claim that proteasome-generated spliced peptides are important [155–157]. There is even evidence that pMHC complexes can be transferred between cells [158]!

Also complicating epitope prediction are post-translational modifications [159, 160] and epitopes found on non-classical MHC proteins like HLA-E [161–163].

Sample heterogeneity

With DNA and/or RNA sequencing data from bulk tissue, it is sometimes possible to estimate the relative proportion of immune cell types present in the sample. This computation is referred to as “deconvolution” [164, 165] and usually relies on the identification of “signature” genes whose expression levels can be used to distinguish between cell types [166]. Software tools for immune infiltrate deconvolution include CIBERSORT [167], TIMER [168], and MCP-counter [169].

These tools are often trained on expression data from isolated immune cell subtypes such as those generated by the Immunological Genome Project (ImmGen) [170] and differ in the number and kind of cell subtypes estimated: TIMER estimates 6 immune cell subtypes, MCP-counter estimates 8 immune cell subtypes and 2 stromal cell subtypes, and CIBERSORT estimates 22 immune cell subtypes. CIBERSORT and TIMER estimate relative frequencies of immune cell subtypes while MCP-counter can estimate absolute abundances. Users should take care when using CIBERSORT on RNA-seq data, as the model is trained on expression array data.

Pathway analysis

Tools for gene set and pathway analysis can be used on populations of immune cells just as they can be on cancer cells. While gene sets and pathways for immune cell behaviors such as antigen processing, interferon response, and cytolysis are available from many of the same databases that hold data on cancer pathways, there are also immune-specific databases like DC-ATLAS [171] and InnateDB [172].

Adaptive immune receptor repertoire sequencing


New library preparation, sequencing, and analysis technologies have enabled the high-throughput sequencing of B and T cell receptor repertoires [173–175]. The original protocols could only sequence unpaired single chains of these receptors; recent protocols make it possible to sequence paired chains [176, 177] to give a complete picture of the receptor repertoire. New algorithms allow repertoire sequences to be extracted from DNA-seq or RNA-seq data from bulk tissue [178–180] or single cells [181].

Public databases of repertoire sequences [182] allow individual samples to be placed into a larger context, and the community is actively working to standardize file formats and processing pipelines [183, 184].

Repertoire sequence populations can be summarized and compared across conditions to understand vaccination [185], aging [186], and more [187, 188]. Receptor diversity is an often-computed summary metric [189], and individual receptors are frequently grouped into clonal families as an intermediate step in these analyses [190]. The Repertoire Dissimilarity Index is another recently proposed measure that can be used to compare two samples [191].

Cancer-immune interactions

Cancer and the immune system are both complex entities that interact and evolve over time. Milestones in the analysis of their interactions include work on cancer immunosurveillance [192–194], immunoediting [195–198], immune escape [199], and the cancer-immunity cycle [200].



Cancer antigens

What are the specific targets of the T cell response to cancer [201]? Many are self-antigens that are aberrantly expressed or post-translationally modified [202], while others are non-self viral [203] or somatic mutation-derived tumor antigens [204]. Somatic mutation-derived tumor antigens are also called “neoantigens” and are important targets for tumor rejection [205–210].

The feasibility of identifying neoantigens with whole exome DNA-seq data was demonstrated in 2008 [211] and has since been used to interrogate the neoantigen-directed response in many cancers including CLL [212]. Open source software for computing neoantigens from sequencing data includes Epidisco [213], ProTECT [214], and pVAC-Seq [215]. The TRON Cell Line Portal (TCLP) catalogs predicted neoantigens for common cancer cell lines [216]; The Cancer Immunome Atlas (TCIA) does the same for 20 solid tumor types from TCGA [217]. A recent analysis of predicted neoantigens for over 60,000 patients found very few shared neoantigens [218].

Recently it has become possible to directly identify peptides presented by cancer cells biopsied from human patients using mass spectrometry [219] and to screen for T cells specific for >1,000

peptide targets in a single tumor sample with high-throughput MHC tetramer assays [220]. Data from these assays is expected to improve the quality of cancer neoantigen prediction.

While the neoantigen burden of a tumor associates with patient survival [221], this effect cannot be separated from the impact of mutation burden [222]. The field is currently working to determine if specific mutagenic processes like chemotherapy are more likely to create neoantigens than others [96], and if certain kinds of neoantigens are more predictive of response than others. It is common to use RNA-seq data to lower the ranking of neopeptides with no evidence of expression and to exclude neopeptides determined to be similar to self-peptides. HLA binding affinity of validated neopeptides and their corresponding unmutated wild type peptides have been closely examined with mixed results [223, 224]. Clonal neoantigens appear to be better than subclonal ones at eliciting a productive anti-tumor immune response [225].

Tumor-intrinsic immune escape

As tumors grow, their constituent clones evolve to evade the immune system [226–229]. Some direct mechanisms of evasion include resistance to T cell lysis [230], or elimination of T cell targets through downregulation of the APM or editing out cancer antigens [134, 231]. Cancer cells also upregulate inhibitory checkpoint ligands such as PD-L1 through a variety of mechanisms [232–236]. While the impact of interferon on cancer cells is complex and still being elucidated, there is strong evidence that the disruption of interferon response pathways plays an important role in immune evasion [237–239].

Sometimes pathways whose primary function upon activation is to equip the tumor with a hallmark of cancer behavior have immune suppression as a secondary function, such as the MAPK [240, 241] and WNT [242] pathways. Recent evidence indicates that large chromosomal disruptions, common in cancer cells, may aid immune evasion [243].

Local immune response

Software for the deconvolution of immune cells in a tissue sample can be used to measure the local immune response to a tumor. Research in colorectal cancer demonstrated that the “immune contexture” of the tumor could be used to predict patient survival [244–247]. Tumors heavily infiltrated by anti-cancer immune cells are said to have “hot” tumor microenvironments (TMEs); tumors that are devoid of tumor infiltrating immune populations are considered “cold” [248]. Researchers have associated positive patient outcomes to effector T cells and mature dendritic cells [249] and poor outcomes to regulatory T cells [250, 251], myeloid-derived suppressor cells (MDSCs) [252], and tumor-associated macrophages (TAMs) [253, 254]. The poor outcomes may be related to immune infiltrate promoting metastasis [255].

The local immune response can be characterized not just by the cell types present but also by the states of those cells and their specific targets in the tumor. A recently proposed “cytolytic signature” attempts to capture cancer cell-killing activity of immune cells in the TME [256]. Other

work has used MHC multimer staining [257, 258] and TCR-seq of tumor-infiltrating lymphocytes (TILs) [259–261] to enumerate the targets and magnitude of the local T cell response to cancer.

While the immune contexture can be deconvolved from RNA-seq of a bulk tumor sample, other measurements may provide more insight. Recent work has shown that the epigenetic profile of a cell, as measured by ATAC-seq, is more stable than RNA-seq of cells of the same type or in the same state [262]. Deconvolution algorithms that take ATAC-seq data as input will likely be more accurate than those that use RNA-seq. It is also likely that high-dimensional single-cell profiling technologies like mass cytometry or single-cell RNA-seq will provide a more detailed understanding of the immune contexture.

Immunohistochemistry (IHC) images capture the spatial distribution of immune cells, and new multiplex protocols allow staining of up to a few dozen antigens on a single slide [263, 264]. Beyond IHC, new techniques like histo-cytometry [265] and multiplexed ion beam imaging (MIBI) [266] make high dimensional quantification of cells possible while capturing their spatial distribution.

Tumor-extrinsic immune escape

The TME is more than just tumor and immune cells: stromal cells, blood and lymphatic vessels, extracellular matrix, interstitial fluid, and microbiota all contribute to the immunogenicity of a tumor [267, 268]. The tumor vasculature is usually studied through the lens of preventing angiogenesis to starve the tumor of nutrients [269]. Blood vessels, however, also permit T cell trafficking to tumors and can be altered in cancer to facilitate immune escape [270, 271]. Tumors can also develop local lymphatics whose role in the immune response to cancer is still being elucidated [272].

Stromal cells modulate the immune contexture of the TME in multiple ways, including altering the contents of the tumor interstitial fluid or remodelling the extracellular matrix to exclude immune cells [273, 274]. They are also an important source of inhibitory checkpoint ligands [275]. Features of the extracellular environment that alter the immune contexture of the TME include ion [276], cytokine [277], and oxygen [278] concentrations, and the tumor microbiome [279, 280]. A particular area of recent focus is the competition for metabolites between clonally expanding tumor and T cells [281, 282]. While DNA-seq and RNA-seq data from tumor biopsies can be used to look for pathways known to modulate the TME, investigation of tumor-extrinsic immune escape is aided significantly by metabolomic data [283].

Systemic immune response

Measurement of the tumor draining or sentinel lymph node [284] as well as profiling of the peripheral blood [285] can provide additional information about the immune response to cancer [286, 287]. In addition, the diversity of the peripheral adaptive immune receptor repertoire can be predictive of disease progression [288, 289], and probing the antigen specificity of the antibody [290] or T cell [291] repertoire can reveal an immune response to tumor antigens.

PhIP-seq is a new technology that allows for low cost, high-throughput profiling of the antigen specificity of the antibody repertoire [292, 293].


Finally, it is well known that cancer incidence increases with age. Measures of aging in the immune system [294] could potentially be used to predict tumor/immune interactions and guide treatment decisions [295].

Summary measures

Recently, it was suggested that the various measures of tumor/immune interactions should be integrated into a single “immunogram” [296, 297] or “immunophenotype” [217, 298, 299]. These summary measures and visualizations can be useful for identifying immune molecular subtypes, prognosis, and clinical decision support, or suggesting new combination therapies [300].

Therapeutic interventions

The understanding gained from studying the interaction of the immune system and cancer can be used to design interventions that improve the immune response to cancer. While conventional cancer therapies have immunological effects [301, 302], here, three approaches to cancer immunotherapy will be discussed: therapeutic vaccination, checkpoint modulation, and adoptive cell transfer (ACT).



Vaccination

In 2010, the FDA approved sipuleucel-T, a dendritic cell vaccine targeting the tumor antigen prostatic acid phosphatase, for use in prostate cancer [303]. Since 2011, CIMAvax-EGF, a vaccine targeting the growth factor receptor ligand EGF in lung cancer [304, 305], has been available in Cuba and is currently in clinical trials in the United States.

These approvals came after decades of development of many approaches to vaccination against established cancer [306–308] and inspired dozens of additional clinical trials [309–311].

Therapeutic cancer vaccines differ by target, delivery method, and adjuvants [312–315]. The major challenge in therapeutic cancer vaccination is not generating a tumor-directed immune response but rather overcoming immune evasion [316] and generating T cell memory [317]. Recently, several approaches to the personalization of therapeutic cancer vaccines have been proposed [318], including loading dendritic cells with material obtained from the tumor directly [319] or specifically targeting neoantigens [320–322].

The efficacy of neoantigen vaccines was demonstrated in mouse models in 2014 [258], and the first publication of results in human trials was in 2015 [323]. The neoantigens targeted by these vaccines are often identified by neoepitope prediction from sequencing or mass spectrometry data [324], though ranking factors may need to be tuned to this task: what makes a good endogenous neoantigen may not be identical to what makes a good target for neoantigen vaccination.

One surprising finding from the analysis of the first neoantigen vaccine responses was that class II epitopes are important for vaccine effectiveness even when vaccine epitopes are predicted based on MHC I prediction algorithms [325, 326]. An important concern with neoantigen vaccines is that some tumors may not have enough neoantigen-generating mutations to target [327].

In addition to target selection, bioinformatics can be used to optimize vaccine delivery and adjuvant composition. Prediction of how the breadth, intensity, and duration of the immune response to vaccination relate to antigen load, schedule, and injection site is an active area of research [328–331].

Checkpoint modulation

The relatively recent success of checkpoint blockade therapies in melanoma [332], followed by other malignancies [333–336], has motivated a resurgence of research into immune checkpoint receptors and their ligands [337, 338]. The FDA has approved antibodies targeting CTLA-4 and PD-1/PD-L1, and new immune checkpoint targets are the subject of active investigation [339–343].

Because pembrolizumab was first approved in conjunction with a companion diagnostic, the IHC 22C3 pharmDx test [344, 345], there has been an intense focus on the association of PD-L1 level with response to blockade of the PD-1/PD-L1 axis [346]. Using PD-L1 level as a biomarker is difficult: PD-L1 is expressed by many cell types, its expression in those cells varies over time [275], its function varies depending on the cell type on which it is expressed [347], there are multiple causes of its presence or absence [348, 349], and it appears to interact with other biomarkers [350]. Nevertheless, work continues in order to understand the role of PD-L1 expression in response to other therapies [351] and in other indications [352]. The Blueprint PD-L1 IHC Assay Comparison Project recently reported their Phase 1 results comparing four assays for measuring PD-L1 [353].

Beyond immune checkpoint receptor or ligand expression, commonly proposed biomarkers for response to checkpoint blockade include mutation burden [354–356], mismatch-repair status [357], and loss of the interferon response pathway [358–361]. The composition of the gut microbiome [362, 363] and overall immune system state (as inferred from peripheral blood samples) [364–366] have also been implicated.

A major challenge for the field is to formulate a mechanistic model of checkpoint blockade that will allow predictive biomarkers that associate with response to intervention to be separated from prognostic biomarkers that associate with disease progression unrelated to intervention [367–369]. Lessons about which cells respond to checkpoint blockade from chronic infection [262, 370] may be important in the construction of the mechanistic models.

Additional challenges include finding biomarkers that predict adverse events [371–373], developing on-treatment biomarkers that predict response to therapy early in the course of treatment [374, 375], and the interpretation of predictive models to elucidate mechanisms of resistance [376] and suggest new combination therapies [377–379].

Adoptive cell transfer

In 1988, it was reported that TILs from melanoma, when expanded *in vitro* and reinfused into the host, could cause tumor regression [380]. In 2002, host lymphodepletion prior to adoptive cell transfer (ACT) was used to improve response rates [381]. For many tumors, however, TILs are not available, and T cells specific for tumor antigens are created *in vitro* through genome editing. Autologous lymphocytes from the peripheral blood edited to express either a cancer antigen-specific TCR [382] or a cell-type specific chimeric antigen receptor (CAR) [383] have been used to treat cancer in humans. For more detailed reviews of ACT, see [384] and [385].

One primary use of bioinformatics in ACT is to identify new targets for cell therapy [386–388]. Similar techniques to those used to discover targets for vaccination are employed in this domain. Bioinformatics can also examine how the targets evolve in response to ACT [389, 390].

To determine the optimal cell product, detailed measurements are performed on cells prior to and after transfer. An increase in the number of T cell targets [391] and the persistence of anti-tumor T cells [392] are post-transfer features associated with positive outcomes. Evolving technologies enable more detailed tracking of the fate of adoptively transferred cells *in vivo* [393], including with PET [394–396].

Another use of bioinformatics in ACT is to discover the expansion and enrichment protocol that generates the optimal cell product for reinfusion. Cytokines [397], metabolites [398], and small molecules [399] have all been shown to impact therapeutic efficacy. Artificial antigen presenting cells (aAPCs) can also be used [400].

Finally, informatics can help determine how to best prepare the patient for ACT. Total body irradiation and chemotherapy are commonly used to deplete lymphocytes in the host prior to ACT; it is not yet clear whether intensive myeloablative lymphodepletion, which requires hematopoietic stem cell transplantation (HSCT) to reconstitute the host immune system, is more effective than transient, nonmyeloablative lymphodepletion [401–403].

Conclusion

Informatics techniques to analyze tumors, the tumor microenvironment, and systemic immunity have evolved alongside the increased use of immunomodulatory therapies in cancer. The rate of progress has been dizzying: the first published use of NGS to predict neoantigens involved spreadsheets and manual curation [211]. Just four years later, the Schreiber lab and collaborators had streamlined the process into a pipeline [404]. Immune deconvolution techniques have enriched the types of data that can be extracted from existing RNA-seq or microarray data, giving a more complete picture of the tumor and its immune microenvironment. This deepened understanding is being brought to the next level by techniques such as single cell RNA-seq and multiplex ion beam imaging (MIBI).

However, challenges abound. First, the determination of sample quality and tumor proportion (in the case of human tumor samples) is uncertain and serves as an unstable foundation for the intricate and often elegant work of translational bioinformatics. Second, as demonstrated by the array of software packages that can be used at each stage of the analytic process, there is no single accepted or superior method with which to perform each step. Consequently, research groups working with distinct methods may generate substantially different results and conclusions from the same dataset. Third, the application of statistical methods to the “multi-omics” data being generated poses a substantial challenge, especially given that many translational studies feature small sample sizes and many studied variables: a perfect storm for false discovery, a risk of which the field must be critically aware. Finally, as preclinical data has demonstrated, metabolomics likely play an important role in tumor immunity, but quality data is difficult to collect when using human samples.

As bioinformatics techniques continue to improve, they are likely to play an ever-growing role in the triage of patients to off-the-shelf therapies, as in the case of mutation load with checkpoint blockade agents, or be used to determine what therapy is given, as in the case of vaccination or ACT.

Acknowledgements

The authors would like to thank Arman Aksoy for his input to this review.

Funding

This work was supported by the Parker Institute for Cancer Immunotherapy to [JH] and the National Cancer Institute at the National Institutes of Health Cancer Center Support Grant [grant number 2P30CA008748-48] to [AS].

Disclosures

Jeff Hammerbacher is the principal investigator on a sponsored research agreement with Neon Therapeutics. Alexandra Snyder is a consultant for Neon Therapeutics.

References

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature* 2009; 458(7239):719–724.
2. Mardis ER. Genome sequencing and cancer. *Curr. Opin. Genet. Dev.* 2012; 22(3):245–250.
3. Ding L, Wendl MC, McMichael JF, Raphael BJ. Expanding the computational toolbox for mining cancer genomes. *Nat. Rev. Genet.* 2014; 15(8):556–570.
4. Martincorena I, Roshan A, Gerstung M et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. *Science* 2015; 348(6237):880–886.
5. Carter SL, Cibulskis K, Helman E et al. Absolute quantification of somatic DNA alterations in human cancer. *Nat. Biotechnol.* 2012; 30(5):413–421.
6. Yoshihara K, Shahmoradgoli M, Martínez E et al. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat. Commun.* 2013; 4:2612.
7. Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. *Nat. Commun.* 2015; 6:8971.
8. Nowell PC. The clonal evolution of tumor cell populations. *Science* 1976; 194(4260):23–28.
9. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.* 2012; 366(10):883–892.
10. Ding L, Raphael BJ, Chen F, Wendl MC. Advances for studying clonal evolution in cancer. *Cancer Lett.* 2013; 340(2):212–219.
11. McGranahan N, Swanton C. Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. *Cancer Cell* 2015; 27(1):15–26.
12. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. *Cell* 2017; 168(4):613–628.
13. Scott J, Marusyk A. Somatic clonal evolution: A selection-centric perspective. *Biochim. Biophys. Acta* 2017. doi:10.1016/j.bbcan.2017.01.006.
14. Schwartz R, Schäffer AA. The evolution of tumour phylogenetics: principles and practice. *Nat. Rev. Genet.* 2017. doi:10.1038/nrg.2016.170.
15. Oesper L, Mahmoody A, Raphael BJ. THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. *Genome Biol.* 2013; 14(7):R80.
16. Roth A, Khattra J, Yap D et al. PyClone: statistical inference of clonal population structure in cancer. *Nat. Methods* 2014; 11(4):396–398.

17. Miller CA, White BS, Dees ND et al. SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. *PLoS Comput. Biol.* 2014; 10(8):e1003665.
18. Deshwar AG, Vembu S, Yung CK et al. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. *Genome Biol.* 2015; 16:35.
19. Deveau P, Daage LC, Oldridge D et al. Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. *bioRxiv* 2016:054346.
20. Jiang Y, Qiu Y, Minn AJ, Zhang NR. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. *Proc. Natl. Acad. Sci. U. S. A.* 2016; 113(37):E5528–37.
21. Zhu W, Kuziora M, Creasy T et al. BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data. *Nucleic Acids Res.* 2016; 44(4):e38.
22. Miller CA, McMichael J, Dang HX et al. Visualizing tumor evolution with the fishplot package for R. *BMC Genomics* 2016; 17(1):880.
23. Krzywinski M. Visualizing Clonal Evolution in Cancer. *Mol. Cell* 2016; 62(5):652–656.
24. Subramanian A, Schwartz R. Reference-free inference of tumor phylogenies from single-cell sequencing data. *BMC Genomics* 2015; 16 Suppl 11:S7.
25. Jahn K, Kuipers J, Beerenwinkel N. Tree inference for single-cell data. *Genome Biol.* 2016; 17:86.
26. Zafar H, Tzen A, Navin N et al. SiFit: A Method for Inferring Tumor Trees from Single-Cell Sequencing Data under Finite-site Models. *bioRxiv* 2016:091595.
27. Kuipers J, Jahn K, Beerenwinkel N. Advances in understanding tumour evolution through single-cell sequencing. *Biochim. Biophys. Acta* 2017. doi:10.1016/j.bbcan.2017.02.001.
28. Grossman RL, Heath AP, Ferretti V et al. Toward a Shared Vision for Cancer Genomic Data. *N. Engl. J. Med.* 2016; 375(12):1109–1112.
29. Larson DE, Harris CC, Chen K et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. *Bioinformatics* 2012; 28(3):311–317.
30. Koboldt DC, Zhang Q, Larson DE et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 2012; 22(3):568–576.
31. Fan Y, Xi L, Hughes DST et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. *Genome Biol.* 2016; 17(1):178.
32. Alioto TS, Buchhalter I, Derdak S et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nat. Commun.* 2015; 6:10001.

33. Cibulskis K, Lawrence MS, Carter SL et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* 2013; 31(3):213–219.
34. Saunders CT, Wong WSW, Swamy S et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. *Bioinformatics* 2012; 28(14):1811–1817.
35. Fang LT, Afshar PT, Chhibber A et al. An ensemble approach to accurately detect somatic mutations using SomaticSeq. *Genome Biol.* 2015; 16:197.
36. Kim SY, Jacob L, Speed TP. Combining calls from multiple somatic mutation-callers. *BMC Bioinformatics* 2014; 15(1):154.
37. Greenman CD, Pleasance ED, Newman S et al. Estimation of rearrangement phylogeny for cancer genomes. *Genome Res.* 2012; 22(2):346–361.
38. Rausch T, Zichner T, Schlattl A et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* 2012; 28(18):i333–i339.
39. Yang L, Luquette LJ, Gehlenborg N et al. Diverse mechanisms of somatic structural variations in human cancer genomes. *Cell* 2013; 153(4):919–929.
40. Chong Z, Ruan J, Gao M et al. novoBreak: local assembly for breakpoint detection in cancer genomes. *Nat. Methods* 2017; 14(1):65–67.
41. Liu S, Tsai W-H, Ding Y et al. Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. *Nucleic Acids Res.* 2016; 44(5):e47.
42. Kumar S, Vo AD, Qin F, Li H. Comparative assessment of methods for the fusion transcripts detection from RNA-Seq data. *Sci. Rep.* 2016; 6:21597.
43. Benelli M, Pescucci C, Marseglia G et al. Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. *Bioinformatics* 2012; 28(24):3232–3239.
44. Jia W, Qiu K, He M et al. SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. *Genome Biol.* 2013; 14(2):R12.
45. Nicorici D, Satalan M, Edgren H et al. FusionCatcher - a tool for finding somatic fusion genes in paired-end RNA-sequencing data. *bioRxiv* 2014:011650.
46. Davidson NM, Majewski IJ, Oshlack A. JAFFA: High sensitivity transcriptome-focused fusion gene detection. *Genome Med.* 2015; 7(1):43.
47. Zack TI, Schumacher SE, Carter SL et al. Pan-cancer patterns of somatic copy number alteration. *Nat. Genet.* 2013; 45(10):1134–1140.
48. Zhao M, Wang Q, Wang Q et al. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. *BMC Bioinformatics* 2013; 14 Suppl 11:S1.
49. Nam J-Y, Kim NKD, Kim SC et al. Evaluation of somatic copy number estimation tools for

- whole-exome sequencing data. *Brief. Bioinform.* 2016; 17(2):185–192.
50. Amarasinghe KC, Li J, Hunter SM et al. Inferring copy number and genotype in tumour exome data. *BMC Genomics* 2014; 15:732.
 51. Magi A, Tattini L, Cifola I et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. *Genome Biol.* 2013; 14(10):R120.
 52. Mosen-Ansorena D, Telleria N, Veganzones S et al. seqCNA: an R package for DNA copy number analysis in cancer using high-throughput sequencing. *BMC Genomics* 2014; 15:178.
 53. Favero F, Joshi T, Marquard AM et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. *Ann. Oncol.* 2015; 26(1):64–70.
 54. San Lucas FA, Sivakumar S, Vattathil S et al. Rapid and powerful detection of subtle allelic imbalance from exome sequencing data with hapLOHseq. *Bioinformatics* 2016; 32(19):3015–3017.
 55. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. *PLoS Comput. Biol.* 2016; 12(4):e1004873.
 56. Hiltmann S, Jenster G, Trapman J et al. Discriminating somatic and germline mutations in tumour DNA samples without matching normals. *Genome Res.* 2015. doi:10.1101/gr.183053.114.
 57. Wilkerson MD, Cabanski CR, Sun W et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. *Nucleic Acids Res.* 2014; 42(13):e107.
 58. Radenbaugh AJ, Ma S, Ewing A et al. RADIA: RNA and DNA integrated analysis for somatic mutation detection. *PLoS One* 2014; 9(11):e111516.
 59. Kokkat TJ, Patel MS, McGarvey D et al. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. *Biopreserv. Biobank.* 2013; 11(2):101–106.
 60. Hedegaard J, Thorsen K, Lund MK et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. *PLoS One* 2014; 9(5):e98187.
 61. Bao R, Huang L, Andrade J et al. Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing. *Cancer Inform.* 2014; 13(Suppl 2):67–82.
 62. Ewels P, Magnusson M, Lundin S, Källér M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* 2016; 32(19):3047–3048.
 63. Doig K, Papenfuss AT, Fox S. Clinical cancer genomic analysis: data engineering required. *Lancet Oncol.* 2015; 16(9):1015–1017.

64. Robinson JT, Thorvaldsdóttir H, Winckler W et al. Integrative genomics viewer. *Nat. Biotechnol.* 2011; 29(1):24–26.
65. Vanderkam D, Aksoy BA, Hodes I et al. pileup.js: a JavaScript library for interactive and in-browser visualization of genomic data. *Bioinformatics* 2016; 32(15):2378–2379.
66. Rashid M, Robles-Espinoza CD, Rust AG, Adams DJ. Cake: a bioinformatics pipeline for the integrated analysis of somatic variants in cancer genomes. *Bioinformatics* 2013; 29(17):2208–2210.
67. Bao R, Hernandez K, Huang L et al. ExScalibur: A High-Performance Cloud-Enabled Suite for Whole Exome Germline and Somatic Mutation Identification. *PLoS One* 2015; 10(8):e0135800.
68. do Valle ÍF, Giampieri E, Simonetti G et al. Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data. *BMC Bioinformatics* 2016; 17(12):27–35.
69. Kuderer NM, Burton KA, Blau S et al. Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. *JAMA Oncol* 2016. doi:10.1001/jamaoncol.2016.4983.
70. Qiu P, Pang L, Arreaza G et al. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. *Int. J. Mol. Sci.* 2016. doi:10.3390/ijms17050651.
71. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. *BMC Bioinformatics* 2013; 14:189.
72. Ewing AD, Houlahan KE, Hu Y et al. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. *Nat. Methods* 2015; 12(7):623–630.
73. Beck TF, Mullikin JC, NISC Comparative Sequencing Program, Biesecker LG. Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin. Chem.* 2016; 62(4):647–654.
74. Griffith M, Miller CA, Griffith OL et al. Optimizing cancer genome sequencing and analysis. *Cell Syst* 2015; 1(3):210–223.
75. Buchhalter I, Hutter B, Alioto TS et al. A comprehensive multicenter comparison of whole genome sequencing pipelines using a uniform tumor-normal sample pair. *bioRxiv* 2014:013177.
76. Zook JM, Chapman B, Wang J et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. *Nat. Biotechnol.* 2014; 32(3):246–251.
77. McLaren W, Gil L, Hunt SE et al. The Ensembl Variant Effect Predictor. *Genome Biol.* 2016; 17(1):122.

78. Cingolani P, Platts A, Wang LL et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly* 2012; 6(2):80–92.
79. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nat. Protoc.* 2015; 10(10):1556–1566.
80. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010; 38(16):e164.
81. Ramos AH, Lichtenstein L, Gupta M et al. Oncotator: cancer variant annotation tool. *Hum. Mutat.* 2015; 36(4):E2423–9.
82. Flicek P, Amode MR, Barrell D et al. Ensembl 2014. *Nucleic Acids Res.* 2014; 42(Database issue):D749–55.
83. Aken BL, Ayling S, Barrell D et al. The Ensembl gene annotation system. *Database* 2016. doi:10.1093/database/baw093.
84. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. *Nucleic Acids Res.* 2007; 35(Database issue):D61–5.
85. Hsu F, Kent WJ, Clawson H et al. The UCSC Known Genes. *Bioinformatics* 2006; 22(9):1036–1046.
86. Forbes SA, Beare D, Gunasekaran P et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res.* 2015; 43(Database issue):D805–11.
87. Griffith M, Spies NC, Krysiak K et al. CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer. *bioRxiv* 2016:072892.
88. Huang L, Fernandes H, Zia H et al. The Precision Medicine Knowledge Base: an online application for collaborative editing, maintenance and sharing of structured clinical-grade cancer mutations interpretations. *bioRxiv* 2016:059824.
89. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. *J. Clin. Oncol.* 2013; 31(15):1825–1833.
90. Zhao S, Zhang B. A comprehensive evaluation of ensembl, RefSeq, and UCSC annotations in the context of RNA-seq read mapping and gene quantification. *BMC Genomics* 2015; 16(1):97.
91. Frankish A, Uszczyńska B, Ritchie GRS et al. Comparison of GENCODE and RefSeq gene annotation and the impact of reference geneset on variant effect prediction. *BMC Genomics* 2015; 16 Suppl 8:S2.
92. McCarthy DJ, Humburg P, Kanapin A et al. Choice of transcripts and software has a large effect on variant annotation. *Genome Med.* 2014; 6(3):26.

93. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. *Nature* 2013; 500(7463):415–421.
94. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. *Nat. Rev. Cancer* 2015; 16(1):35–42.
95. Alexandrov LB, Ju YS, Haase K et al. Mutational signatures associated with tobacco smoking in human cancer. *Science* 2016; 354(6312):618–622.
96. O'Donnell T, Christie EL, Buros J et al. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. *bioRxiv* 2016:090134.
97. Rosenthal R, McGranahan N, Herrero J et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Biol.* 2016; 17(1):31.
98. Petljak M, Alexandrov LB. Understanding mutagenesis through delineation of mutational signatures in human cancer. *Carcinogenesis* 2016; 37(6):531–540.
99. De Sousa E Melo F, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity--a multifaceted view. *EMBO Rep.* 2013; 14(8):686–695.
100. Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. *Hum. Genomics* 2015; 9:27.
101. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015; 517(7536):576–582.
102. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* 2013; 499(7456):43–49.
103. Hoadley KA, Yau C, Wolf DM et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* 2014; 158(4):929–944.
104. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144(5):646–674.
105. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. *PLoS Comput. Biol.* 2012; 8(2):e1002375.
106. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. *Science* 2013; 339(6127):1546–1558.
107. Consequences TM, Pathway Analysis working group of the International Cancer Genome Consortium. Pathway and network analysis of cancer genomes. *Nat. Methods* 2015; 12(7):615–621.
108. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000; 28(1):27–30.
109. Kanehisa M, Sato Y, Kawashima M et al. KEGG as a reference resource for gene and

- protein annotation. *Nucleic Acids Res.* 2016; 44(D1):D457–62.
110. Araki H, Knapp C, Tsai P, Print C. GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis. *FEBS Open Bio* 2012; 2:76–82.
 111. Liberzon A, Birger C, Thorvaldsdóttir H et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 2015; 1(6):417–425.
 112. Fabregat A, Sidiropoulos K, Garapati P et al. The Reactome pathway Knowledgebase. *Nucleic Acids Res.* 2016; 44(D1):D481–7.
 113. Mootha VK, Lindgren CM, Eriksson K-F et al. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 2003; 34(3):267–273.
 114. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* 2005; 102(43):15545–15550.
 115. Alhamdoosh M, Ng M, Wilson NJ et al. Combining multiple tools outperforms individual methods in gene set enrichment analyses. *Bioinformatics* 2016. doi:10.1093/bioinformatics/btw623.
 116. Ahn T, Lee E, Huh N, Park T. Personalized identification of altered pathways in cancer using accumulated normal tissue data. *Bioinformatics* 2014; 30(17):i422–9.
 117. Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* 2009; 462(7269):108–112.
 118. Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013; 14:7.
 119. Meng C, Kuster B, Peters B et al. moGSA: integrative single sample gene-set analysis of multiple omics data. *bioRxiv* 2016:046904.
 120. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat. Immunol.* 2013; 14(10):1014–1022.
 121. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. *Annu. Rev. Immunol.* 2009; 27:591–619.
 122. Swain SL. T cell subsets and the recognition of MHC class. *Immunol. Rev.* 1983; 74:129–142.
 123. Lefranc M-P, Giudicelli V, Ginestoux C et al. IMGT®, the international ImMunoGeneTics information system®. *Nucleic Acids Res.* 2009; 37(suppl_1):D1006–D1012.
 124. Erlich H. HLA DNA typing: past, present, and future. *Tissue Antigens* 2012; 80(1):1–11.
 125. Liu C, Yang X, Duffy B et al. ATHLATES: accurate typing of human leukocyte antigen

- through exome sequencing. *Nucleic Acids Res.* 2013; 41(14):e142.
126. Shukla SA, Rooney MS, Rajasagi M et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. *Nat. Biotechnol.* 2015; 33(11):1152–1158.
 127. Boegel S, Löwer M, Schäfer M et al. HLA typing from RNA-Seq sequence reads. *Genome Med.* 2012; 4(12):102.
 128. Szolek A, Schubert B, Mohr C et al. OptiType: precision HLA typing from next-generation sequencing data. *Bioinformatics* 2014; 30(23):3310–3316.
 129. Kiyotani K, Mai TH, Nakamura Y. Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. *J. Hum. Genet.* 2016. doi:10.1038/jhg.2016.141.
 130. Chang C-J, Chen P-L, Yang W-S, Chao K-M. A fault-tolerant method for HLA typing with PacBio data. *BMC Bioinformatics* 2014; 15:296.
 131. Ammar R, Paton TA, Torti D et al. Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. *F1000Res.* 2015; 4:17.
 132. Cereb N, Kim HR, Ryu J, Yang SY. Advances in DNA sequencing technologies for high resolution HLA typing. *Hum. Immunol.* 2015; 76(12):923–927.
 133. Dilthey AT, Gourraud P-A, Mentzer AJ et al. High-Accuracy HLA Type Inference from Whole-Genome Sequencing Data Using Population Reference Graphs. *PLoS Comput. Biol.* 2016; 12(10):e1005151.
 134. Leone P, Shin E-C, Perosa F et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. *J. Natl. Cancer Inst.* 2013; 105(16):1172–1187.
 135. Vita R, Overton JA, Greenbaum JA et al. The immune epitope database (IEDB) 3.0. *Nucleic Acids Res.* 2015; 43(Database issue):D405–12.
 136. Tenzer S, Peters B, Bulik S et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. *Cell. Mol. Life Sci.* 2005; 62(9):1025–1037.
 137. Sette A, Vitiello A, Rehman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. *J. Immunol.* 1994; 153(12):5586–5592.
 138. Nielsen M, Lundegaard C, Blicher T et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. *PLoS One* 2007; 2(8):e796.
 139. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. *Bioinformatics* 2008; 24(11):1397–1398.

140. Karosiene E, Rasmussen M, Blicher T et al. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. *Immunogenetics* 2013; 65(10):711–724.
141. Trolle T, Metushi IG, Greenbaum JA et al. Automated benchmarking of peptide-MHC class I binding predictions. *Bioinformatics* 2015; 31(13):2174–2181.
142. Kim Y, Sidney J, Pinilla C et al. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. *BMC Bioinformatics* 2009; 10:394.
143. Rubinsteyn A, O'Donnell T, Damaraju N, Hammerbacher J. Predicting Peptide-MHC Binding Affinities With Imputed Training Data. *bioRxiv* 2016:054775.
144. Moutaftsi M, Peters B, Pasquetto V et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. *Nat. Biotechnol.* 2006; 24(7):817–819.
145. Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. *Nat. Rev. Immunol.* 2015; 15(4):203–216.
146. Lund O, Karosiene E, Lundegaard C et al. Bioinformatics identification of antigenic peptide: predicting the specificity of major MHC class I and II pathway players. *Methods Mol. Biol.* 2013; 960:247–260.
147. Caron E, Kowalewski DJ, Chiek Koh C et al. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. *Mol. Cell. Proteomics* 2015; 14(12):3105–3117.
148. Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. *Mol. Cell. Proteomics* 2015; 14(3):658–673.
149. Pearson H, Daouda T, Granados DP et al. MHC class I-associated peptides derive from selective regions of the human genome. *J. Clin. Invest.* 2016; 126(12):4690–4701.
150. Abelin JG, Keskin DB, Sarkizova S et al. Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. *Immunity* 2017; 46(2):315–326.
151. Birnbaum ME, Mendoza JL, Sethi DK et al. Deconstructing the peptide-MHC specificity of T cell recognition. *Cell* 2014; 157(5):1073–1087.
152. Zhang S-Q, Parker P, Ma K-Y et al. Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells. *Sci. Transl. Med.* 2016; 8(341):341ra77.
153. Apcher S, Prado Martins R, Fåhræus R. The source of MHC class I presented peptides and its implications. *Curr. Opin. Immunol.* 2016; 40:117–122.
154. Yewdell JW, Antón LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? *J. Immunol.* 1996;

- 157(5):1823–1826.
155. Berkers CR, de Jong A, Schuurman KG et al. Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage. *J. Immunol.* 2015; 195(9):4075–4084.
 156. Liepe J, Marino F, Sidney J et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. *Science* 2016; 354(6310):354–358.
 157. Delong T, Wiles TA, Baker RL et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. *Science* 2016; 351(6274):711–714.
 158. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. *J. Immunol.* 2006; 177(9):6018–6024.
 159. Luban S, Li Z-G. Citrullinated peptide and its relevance to rheumatoid arthritis: an update. *Int. J. Rheum. Dis.* 2010; 13(4):284–287.
 160. Mohammed F, Cobbold M, Zarling AL et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. *Nat. Immunol.* 2008; 9(11):1236–1243.
 161. de Kruijf EM, Sajet A, van Nes JGH et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. *J. Immunol.* 2010; 185(12):7452–7459.
 162. Zeestraten ECM, Reimers MS, Saadatmand S et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. *Br. J. Cancer* 2014; 110(2):459–468.
 163. Hansen SG, Wu HL, Burwitz BJ et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. *Science* 2016; 351(6274):714–720.
 164. Abbas AR, Wolslegel K, Seshasayee D et al. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. *PLoS One* 2009; 4(7):e6098.
 165. Shen-Orr SS, Gaujoux R. Computational deconvolution: extracting cell type-specific information from heterogeneous samples. *Curr. Opin. Immunol.* 2013; 25(5):571–578.
 166. Abbas AR, Baldwin D, Ma Y et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. *Genes Immun.* 2005; 6(4):319–331.
 167. Newman AM, Liu CL, Green MR et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* 2015; 12(5):453–457.
 168. Li B, Severson E, Pignon J-C et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. *Genome Biol.* 2016; 17(1):174.
 169. Becht E, Giraldo NA, Lacroix L et al. Estimating the population abundance of

- tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol.* 2016; 17(1):218.
170. Heng TSP, Painter MW, Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. *Nat. Immunol.* 2008; 9(10):1091–1094.
 171. Cavalieri D, Rivero D, Beltrame L et al. DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. *Immunome Res.* 2010; 6:10.
 172. Breuer K, Foroushani AK, Laird MR et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. *Nucleic Acids Res.* 2013; 41(Database issue):D1228–33.
 173. Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. Rep-Seq: uncovering the immunological repertoire through next-generation sequencing. *Immunology* 2012; 135(3):183–191.
 174. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. *J. Immunol.* 2012; 189(6):3221–3230.
 175. Boyd SD, Marshall EL, Merker JD et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. *Sci. Transl. Med.* 2009; 1(12):12ra23.
 176. Howie B, Sherwood AM, Berkebile AD et al. High-throughput pairing of T cell receptor α and β sequences. *Sci. Transl. Med.* 2015; 7(301):301ra131.
 177. Lee ES, Thomas PG, Mold JE, Yates AJ. Identifying T Cell Receptors from High-Throughput Sequencing: Dealing with Promiscuity in TCR α and TCR β Pairing. *PLoS Comput. Biol.* 2017; 13(1):e1005313.
 178. Li B, Li T, Pignon J-C et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nat. Genet.* 2016; 48(7):725–732.
 179. Mangul S, Mandric I, Yang HT et al. Profiling adaptive immune repertoires across multiple human tissues by RNA Sequencing. *bioRxiv* 2016:089235.
 180. Brown SD, Raeburn LA, Holt RA. Profiling tissue-resident T cell repertoires by RNA sequencing. *Genome Med.* 2015; 7:125.
 181. Eltahla AA, Rizzetto S, Pirozyan MR et al. Linking the T cell receptor to the single cell transcriptome in antigen-specific human T cells. *Immunol. Cell Biol.* 2016; 94(6):604–611.
 182. DeWitt WS, Lindau P, Snyder TM et al. A Public Database of Memory and Naive B-Cell Receptor Sequences. *PLoS One* 2016; 11(8):e0160853.
 183. About the AIRR Community. [<http://airr.irmacs.sfu.ca>].
 184. Zhang L, Cham J, Paciorek A et al. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. *BMC*

- Bioinformatics 2017; 18(1):129.
185. Laserson U, Vigneault F, Gadala-Maria D et al. High-resolution antibody dynamics of vaccine-induced immune responses. *Proc. Natl. Acad. Sci. U. S. A.* 2014; 111(13):4928–4933.
 186. de Bourcy CFA, Angel CJL, Vollmers C et al. Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging. *Proc. Natl. Acad. Sci. U. S. A.* 2017. doi:10.1073/pnas.1617959114.
 187. Yaari G, Kleinstein SH. Practical guidelines for B-cell receptor repertoire sequencing analysis. *Genome Med.* 2015; 7:121.
 188. Lindau P, Robins HS. Advances and Applications of Immune Receptor Sequencing in Systems Immunology. *Current Opinion in Systems Biology* 2016. doi:10.1016/j.coisb.2016.12.009.
 189. Greiff V, Bhat P, Cook SC et al. A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status. *Genome Med.* 2015; 7(1):49.
 190. Ralph DK, Matsen FA 4th. Likelihood-Based Inference of B Cell Clonal Families. *PLoS Comput. Biol.* 2016; 12(10):e1005086.
 191. Bolen CR, Rubelt F, Vander Heiden JA, Davis MM. The Repertoire Dissimilarity Index as a method to compare lymphocyte receptor repertoires. *BMC Bioinformatics* 2017; 18(1):155.
 192. Burnet FM. The concept of immunological surveillance. *Prog. Exp. Tumor Res.* 1970; 13:1–27.
 193. Burnet FM. Immunological surveillance in neoplasia. *Transplant. Rev.* 1971; 7:3–25.
 194. Burnet FM. Implications of immunological surveillance for cancer therapy. *Isr. J. Med. Sci.* 1971; 7(1):9–16.
 195. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat. Immunol.* 2002; 3(11):991–998.
 196. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu. Rev. Immunol.* 2004; 22:329–360.
 197. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004; 21(2):137–148.
 198. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. *Science* 2011; 331(6024):1565–1570.
 199. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. *Nat. Immunol.* 2002; 3(11):999–1005.
 200. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*

- 2013; 39(1):1–10.
201. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. *Nat. Rev. Cancer* 2014; 14(2):135–146.
 202. Fu C, Zhao H, Wang Y et al. Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. *Hladnikia* 2016; 88(6):275–286.
 203. Wang XG, Revskaya E, Bryan RA et al. Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. *PLoS One* 2007; 2(10):e1114.
 204. Finnigan JP Jr, Rubinsteyn A, Hammerbacher J, Bhardwaj N. Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy. *Oncology* 2015.
 205. Lennerz V, Fatho M, Gentilini C et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. *Proc. Natl. Acad. Sci. U. S. A.* 2005; 102(44):16013–16018.
 206. Srivastava PK. Neopitopes of Cancers: Looking Back, Looking Ahead. *Cancer Immunol Res* 2015; 3(9):969–977.
 207. Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. *J. Clin. Invest.* 2015; 125(9):3413–3421.
 208. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015; 348(6230):69–74.
 209. Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. *Ann Transl Med* 2016; 4(14):262.
 210. Yarchoan M, Johnson BA 3rd, Lutz ER et al. Targeting neoantigens to augment antitumour immunity. *Nat. Rev. Cancer* 2017. doi:10.1038/nrc.2016.154.
 211. Segal NH, Parsons DW, Peggs KS et al. Epitope landscape in breast and colorectal cancer. *Cancer Res.* 2008; 68(3):889–892.
 212. Rajasagi M, Shukla SA, Fritsch EF et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. *Blood* 2014; 124(3):453–462.
 213. hammerlab/epidisco. [<https://github.com/hammerlab/epidisco>].
 214. BD2KGenomics/protect. [<https://github.com/BD2KGenomics/protect>].
 215. Hundal J, Carreno BM, Petti AA et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. *Genome Med.* 2016; 8(1):11.
 216. Scholtalbers J, Boegel S, Bukur T et al. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. *Genome Med.*

- 2015; 7:118.
217. Charoentong P, Finotello F, Angelova M et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. *Cell Rep.* 2017; 18(1):248–262.
 218. Hartmaier RJ, Charo J, Fabrizio D et al. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. *Genome Med.* 2017; 9(1):16.
 219. Bassani-Sternberg M, Bräunlein E, Klar R et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. *Nat. Commun.* 2016; 7:13404.
 220. Bentzen AK, Marquard AM, Lyngaa R et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. *Nat. Biotechnol.* 2016; 34(10):1037–1045.
 221. Brown SD, Warren RL, Gibb EA et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. *Genome Res.* 2014; 24(5):743–750.
 222. Nathanson T, Ahuja A, Rubinsteyn A et al. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. *Cancer Immunol Res* 2017; 5(1):84–91.
 223. Duan F, Duitama J, Al Seesi S et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. *J. Exp. Med.* 2014; 211(11):2231–2248.
 224. Fritsch EF, Rajasagi M, Ott PA et al. HLA-binding properties of tumor neoepitopes in humans. *Cancer Immunol Res* 2014; 2(6):522–529.
 225. McGranahan N, Furness AJS, Rosenthal R et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* 2016; 351(6280):1463–1469.
 226. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv. Immunol.* 2000; 74:181–273.
 227. Ribas A. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. *Cancer Discov.* 2015; 5(9):915–919.
 228. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. *Nat. Rev. Cancer* 2016; 16(2):121–126.
 229. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* 2017; 168(4):707–723.
 230. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant

- effect in metastatic mouse prostate cancer cells. *Cancer Res.* 2000; 60(7):1927–1933.
231. Restifo NP, Marincola FM, Kawakami Y et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. *J. Natl. Cancer Inst.* 1996; 88(2):100–108.
232. Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. *Nat. Med.* 2007; 13(1):84–88.
233. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2010; 116(17):3268–3277.
234. Lastwika KJ, Wilson W 3rd, Li QK et al. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. *Cancer Res.* 2016; 76(2):227–238.
235. Casey SC, Tong L, Li Y et al. MYC regulates the antitumor immune response through CD47 and PD-L1. *Science* 2016; 352(6282):227–231.
236. Lim S-O, Li C-W, Xia W et al. Deubiquitination and Stabilization of PD-L1 by CSN5. *Cancer Cell* 2016; 30(6):925–939.
237. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. *Proc. Natl. Acad. Sci. U. S. A.* 1998; 95(13):7556–7561.
238. Shankaran V, Ikeda H, Bruce AT et al. IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature* 2001; 410(6832):1107–1111.
239. Dunn GP, Bruce AT, Sheehan KCF et al. A critical function for type I interferons in cancer immunoediting. *Nat. Immunol.* 2005; 6(7):722–729.
240. Liu C, Peng W, Xu C et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. *Clin. Cancer Res.* 2013; 19(2):393–403.
241. Low HB, Zhang Y. Regulatory Roles of MAPK Phosphatases in Cancer. *Immune Netw.* 2016; 16(2):85–98.
242. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 2015; 523(7559):231–235.
243. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. *Science* 2017. doi:10.1126/science.aaf8399.
244. Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and

- survival in colorectal cancer. *N. Engl. J. Med.* 2005; 353(25):2654–2666.
245. Galon J, Fridman W-H, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. *Cancer Res.* 2007; 67(5):1883–1886.
246. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nat. Rev. Cancer* 2012; 12(4):298–306.
247. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. *Curr. Opin. Immunol.* 2013; 25(2):261–267.
248. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. *Curr. Opin. Immunol.* 2016; 41:23–31.
249. Roberts EW, Broz ML, Binnewies M et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. *Cancer Cell* 2016; 30(2):324–336.
250. Whiteside TL. The role of regulatory T cells in cancer immunology. *Immunotargets Ther* 2015; 4:159–171.
251. Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. *Vaccines (Basel)* 2016. doi:10.3390/vaccines4030028.
252. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. *Trends Immunol.* 2016; 37(3):208–220.
253. Szebeni GJ, Vizler C, Nagy LI et al. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. *Int. J. Mol. Sci.* 2016. doi:10.3390/ijms17111958.
254. Guo Q, Jin Z, Yuan Y et al. New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy. *J Immunol Res* 2016; 2016:9720912.
255. Kitamura T, Qian B-Z, Pollard JW. Immune cell promotion of metastasis. *Nat. Rev. Immunol.* 2015; 15(2):73–86.
256. Rooney MS, Shukla SA, Wu CJ et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* 2015; 160(1-2):48–61.
257. van Rooij N, van Buuren MM, Philips D et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J. Clin. Oncol.* 2013; 31(32):e439–42.
258. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature* 2014; 515(7528):577–581.
259. Sainz-Perez A, Lim A, Lemercier B, Leclerc C. The T-cell Receptor Repertoire of Tumor-Infiltrating Regulatory T Lymphocytes Is Skewed Toward Public Sequences. *Cancer*

Res. 2012; 72(14):3557–3569.

260. Nakanishi K, Kukita Y, Segawa H et al. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes. *Cancer Med.* 2016; 5(9):2513–2521.
261. Levy E, Marty R, Gárate Calderón V et al. Immune DNA signature of T-cell infiltration in breast tumor exomes. *Sci. Rep.* 2016; 6:30064.
262. Pauken KE, Sammons MA, Odorizzi PM et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* 2016; 354(6316):1160–1165.
263. Dixon AR, Bathany C, Tsuei M et al. Recent developments in multiplexing techniques for immunohistochemistry. *Expert Rev. Mol. Diagn.* 2015; 15(9):1171–1186.
264. Remark R, Merghoub T, Grabe N et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. *Science Immunology* 2016; 1(1):aaf6925–aaf6925.
265. Gerner MY, Kastenmuller W, Ifrim I et al. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. *Immunity* 2012; 37(2):364–376.
266. Angelo M, Bendall SC, Finck R et al. Multiplexed ion beam imaging of human breast tumors. *Nat. Med.* 2014; 20(4):436–442.
267. Chen F, Zhuang X, Lin L et al. New horizons in tumor microenvironment biology: challenges and opportunities. *BMC Med.* 2015; 13:45.
268. Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. *Nat. Rev. Clin. Oncol.* 2016; 13(3):143–158.
269. Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin. Oncol.* 2002; 29(6 Suppl 16):15–18.
270. Hendry SA, Farnsworth RH, Solomon B et al. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. *Front. Immunol.* 2016; 7:621.
271. Dieterich LC, Ikenberg K, Cetintas T et al. Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. *Front. Immunol.* 2017. doi:10.3389/fimmu.2017.00066.
272. Sautès-Fridman C, Lawand M, Giraldo NA et al. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. *Front. Immunol.* 2016; 7:407.
273. Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. *Gene Expr.* 2014; 16(2):77–84.
274. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor

- microenvironment. *Science* 2015; 348(6230):74–80.
275. Noguchi T, Ward JP, Gubin MM et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. *Cancer Immunol Res* 2017; 5(2):106–117.
276. Eil R, Vodnala SK, Clever D et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. *Nature* 2016; 537(7621):539–543.
277. Atretkhany K-SN, Drutskaya MS, Nedospasov SA et al. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. *Pharmacol. Ther.* 2016; 168:98–112.
278. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology* 2014; 143(4):512–519.
279. Nakatsu G, Li X, Zhou H et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. *Nat. Commun.* 2015; 6:8727.
280. Alfano M, Canducci F, Nebuloni M et al. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. *Nat. Rev. Urol.* 2016; 13(2):77–90.
281. Chang C-H, Qiu J, O’Sullivan D et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. *Cell* 2015; 162(6):1229–1241.
282. Scharping NE, Delgoffe GM. Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. *Vaccines (Basel)* 2016. doi:10.3390/vaccines4040046.
283. Johnson CH, Spilker ME, Goetz L et al. Metabolite and Microbiome Interplay in Cancer Immunotherapy. *Cancer Res.* 2016; 76(21):6146–6152.
284. Rodolfo M, Castelli C, Rivoltini L. Immune response markers in sentinel nodes may predict melanoma progression. *Oncoimmunology* 2014; 3(4):e28498.
285. Gustafson MP, Lin Y, LaPlant B et al. Immune monitoring using the predictive power of immune profiles. *J Immunother Cancer* 2013; 1:7.
286. Zuckerman NS, Yu H, Simons DL et al. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. *Int. J. Cancer* 2013; 132(11):2537–2547.
287. Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: time for integration. *Cancer Immunol. Immunother.* 2014; 63(1):45–57.
288. Manuel M, Tredan O, Bachelot T et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. *Oncoimmunology* 2012; 1(4):432–440.
289. Gazzola A, Mannu C, Rossi M et al. The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. *Ther. Adv. Hematol.* 2014; 5(2):35–47.
290. Frieze KM, Roden RBS, Lee J-H et al. Identification of Anti-CA125 Antibody Responses

- in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform. *Cancer Immunol Res* 2016; 4(2):157–164.
291. Cohen CJ, Gartner JJ, Horovitz-Fried M et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. *J. Clin. Invest.* 2015; 125(10):3981–3991.
 292. Larman HB, Laserson U, Querol L et al. PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. *J. Autoimmun.* 2013; 43:1–9.
 293. Xu GJ, Kula T, Xu Q et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. *Science* 2015; 348(6239):aaa0698.
 294. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc. Biol. Sci.* 2015; 282(1821):20143085.
 295. Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. *Clin. Exp. Immunol.* 2017; 187(1):53–63.
 296. Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The “cancer immunogram.” *Science* 2016; 352(6286):658–660.
 297. Karasaki T, Nagayama K, Kuwano H et al. An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer. *J. Thorac. Oncol.* 2017. doi:10.1016/j.jtho.2017.01.005.
 298. Angelova M, Charoentong P, Hackl H et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. *Genome Biol.* 2015; 16:64.
 299. Lizotte PH, Ivanova EV, Awad MM et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. *JCI Insight* 2016; 1(14):e89014.
 300. Şenbabaoğlu Y, Gejman RS, Winer AG et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol.* 2016; 17(1):231.
 301. Galluzzi L, Buqué A, Kepp O et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. *Cancer Cell* 2015; 28(6):690–714.
 302. Spiotto M, Fu Y-X, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. *Sci Immunol* 2016. doi:10.1126/sciimmunol.aag1266.
 303. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.* 2010; 363(5):411–422.
 304. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. *MEDICC Rev.* 2010; 12(1):17–23.

305. Rodriguez PC, Popa X, Martínez O et al. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. *Clin. Cancer Res.* 2016; 22(15):3782–3790.
306. Finke LH, Wentworth K, Blumenstein B et al. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). *Vaccine* 2007; 25 Suppl 2:B97–B109.
307. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? *Immunol. Rev.* 2011; 239(1):27–44.
308. Guo C, Manjili MH, Subjeck JR et al. Therapeutic cancer vaccines: past, present, and future. *Adv. Cancer Res.* 2013; 119:421–475.
309. Melero I, Gaudernack G, Gerritsen W et al. Therapeutic vaccines for cancer: an overview of clinical trials. *Nat. Rev. Clin. Oncol.* 2014; 11(9):509–524.
310. Clifton GT, Kohrt HE, Peoples GE. Critical issues in cancer vaccine trial design. *Vaccine* 2015; 33(51):7386–7392.
311. Romero P, Banchereau J, Bhardwaj N et al. The Human Vaccines Project: A roadmap for cancer vaccine development. *Sci. Transl. Med.* 2016; 8(334):334ps9.
312. Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants--recent clinical progress and future perspectives. *Immunopharmacol. Immunotoxicol.* 2015; 37(1):1–11.
313. Ye Z, Li Z, Jin H, Qian Q. Therapeutic Cancer Vaccines. *Adv. Exp. Med. Biol.* 2016; 909:139–167.
314. Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. *Methods Mol. Biol.* 2016; 1403:755–761.
315. Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. *Journal for ImmunoTherapy of Cancer* 2016; 4(1):56.
316. van der Burg SH, Arens R, Ossendorp F et al. Vaccines for established cancer: overcoming the challenges posed by immune evasion. *Nat. Rev. Cancer* 2016; 16(4):219–233.
317. van Duikeren S, Fransen MF, Redeker A et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. *J. Immunol.* 2012; 189(7):3397–3403.
318. Ophir E, Bobisse S, Coukos G et al. Personalized approaches to active immunotherapy in cancer. *Biochim. Biophys. Acta* 2016; 1865(1):72–82.
319. Chiang CL-L, Coukos G, Kandalaft LE. Whole Tumor Antigen Vaccines: Where Are We? *Vaccines (Basel)* 2015; 3(2):344–372.
320. Hacohen N, Fritsch EF, Carter TA et al. Getting personal with neoantigen-based

- therapeutic cancer vaccines. *Cancer Immunol Res* 2013; 1(1):11–15.
321. Fritsch EF, Hacoheh N, Wu CJ. Personal neoantigen cancer vaccines: The momentum builds. *Oncoimmunology* 2014; 3:e29311.
 322. Türeci Ö, Vormehr M, Diken M et al. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. *Clin. Cancer Res.* 2016; 22(8):1885–1896.
 323. Carreno BM, Magrini V, Becker-Hapak M et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science* 2015; 348(6236):803–808.
 324. Rammensee H-G, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. *Expert Rev. Vaccines* 2013; 12(10):1211–1217.
 325. Kreiter S, Vormehr M, van de Roemer N et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. *Nature* 2015; 520(7549):692–696.
 326. Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. *Adv. Immunol.* 2016; 130:25–74.
 327. Martin SD, Brown SD, Wick DA et al. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. *PLoS One* 2016; 11(5):e0155189.
 328. McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. *Drug Discov. Today Technol.* 2005; 2(1):89–96.
 329. Characiejus D, Jacobs JJJ, Pašukonienė V et al. Prediction of response in cancer immunotherapy. *Anticancer Res.* 2011; 31(2):639–647.
 330. Henrickson SE, Perro M, Loughhead SM et al. Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions. *Immunity* 2013; 39(3):496–507.
 331. Tschärke DC, Croft NP, Doherty PC, La Gruta NL. Sizing up the key determinants of the CD8(+) T cell response. *Nat. Rev. Immunol.* 2015; 15(11):705–716.
 332. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* 2010; 363(8):711–723.
 333. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* 2015; 373(19):1803–1813.
 334. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387(10031):1909–1920.
 335. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol.*

- 2015; 16(3):257–265.
336. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N. Engl. J. Med.* 2015; 372(4):311–319.
 337. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. *J. Clin. Oncol.* 2015; 33(17):1974–1982.
 338. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 2015; 27(4):450–461.
 339. Giuroiu I, Weber J. Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy. *Cancer J.* 2017; 23(1):23–31.
 340. Janakiram M, Shah UA, Liu W et al. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. *Immunol. Rev.* 2017; 276(1):26–39.
 341. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunol. Rev.* 2017; 276(1):121–144.
 342. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. *Immunol. Rev.* 2017; 276(1):112–120.
 343. Ni L, Dong C. New checkpoints in cancer immunotherapy. *Immunol. Rev.* 2017; 276(1):52–65.
 344. Roach C, Zhang N, Corigliano E et al. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. *Appl. Immunohistochem. Mol. Morphol.* 2016; 24(6):392–397.
 345. Jørgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. *Expert Rev. Mol. Diagn.* 2016; 16(2):131–133.
 346. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. *Onco. Targets. Ther.* 2016; 9:5023–5039.
 347. Lau J, Cheung J, Navarro A et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. *Nat. Commun.* 2017; 8:14572.
 348. Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? *J. Exp. Med.* 2016; 213(13):2835–2840.
 349. Scheel AH, Ansén S, Schultheis AM et al. PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. *Oncoimmunology* 2016; 5(5):e1131379.
 350. Liu X, Cho WC. Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. *Clin. Transl. Med.* 2017; 6(1):7.
 351. Novotny JF Jr, Cogswell J, Inzunza H et al. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. *Ann. Oncol.* 2016; 27(10):1966–1969.

352. Daud AI, Wolchok JD, Robert C et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. *J. Clin. Oncol.* 2016; 34(34):4102–4109.
353. Hirsch FR, McElhinny A, Stanforth D et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *J. Thorac. Oncol.* 2017; 12(2):208–222.
354. Snyder A, Makarov V, Merghoub T et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. *N. Engl. J. Med.* 2014; 371(23):2189–2199.
355. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015; 348(6230):124–128.
356. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 2015; 350(6257):207–211.
357. Le DT, Uram JN, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N. Engl. J. Med.* 2015; 372(26):2509–2520.
358. Gao J, Shi LZ, Zhao H et al. Loss of IFN- γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell* 2016; 167(2):397–404.e9.
359. Benci JL, Xu B, Qiu Y et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell* 2016; 167(6):1540–1554.e12.
360. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N. Engl. J. Med.* 2016; 375(9):819–829.
361. Shi LZ, Fu T, Guan B et al. Interdependent IL-7 and IFN- γ signalling in T-cell controls tumour eradication by combined α -CTLA-4+ α -PD-1 therapy. *Nat. Commun.* 2016; 7:12335.
362. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* 2015; 350(6264):1079–1084.
363. Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* 2015; 350(6264):1084–1089.
364. Snyder A, Nathanson T, Funt S et al. Multi-omic analysis of urothelial cancer patients treated with PD-L1 blockade demonstrates the contribution of both systemic and somatic factors to the biology of response and resistance. *bioRxiv* 2016:086843.
365. Wistuba-Hamprecht K, Martens A, Heubach F et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. *Eur. J. Cancer* 2017; 73:61–70.
366. Spitzer MH, Carmi Y, Reticker-Flynn NE et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. *Cell* 2017; 168(3):487–502.e15.
367. Goshio M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker

- research. *Sensors* 2012; 12(7):8966–8986.
368. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat. Rev. Cancer* 2016; 16(5):275–287.
 369. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. *Lancet Oncol.* 2016; 17(12):e542–e551.
 370. Im SJ, Hashimoto M, Gerner MY et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* 2016; 537(7620):417–421.
 371. Shahabi V, Berman D, Chasalow SD et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. *J. Transl. Med.* 2013; 11:75.
 372. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur. J. Cancer* 2016; 54:139–148.
 373. Kourie HR, Paesmans M, Klastersky J. Biomarkers for adverse events associated with immune checkpoint inhibitors. *Biomark. Med.* 2016; 10(10):1029–1031.
 374. Chen P-L, Roh W, Reuben A et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discov.* 2016; 6(8):827–837.
 375. Lesterhuis WJ, Bosco A, Millward MJ et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. *Nat. Rev. Drug Discov.* 2017. doi:10.1038/nrd.2016.233.
 376. O'Donnell JS, Long GV, Scolyer RA et al. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer Treat. Rev.* 2017; 52:71–81.
 377. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. *Cell* 2015; 161(2):205–214.
 378. Swart M, Verbrugge I, Beltman JB. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. *Front. Oncol.* 2016; 6:233.
 379. Moynihan KD, Opel CF, Szeto GL et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. *Nat. Med.* 2016; 22(12):1402–1410.
 380. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N. Engl. J. Med.* 1988; 319(25):1676–1680.
 381. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 2002; 298(5594):850–854.
 382. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer

- of genetically engineered lymphocytes. *Science* 2006; 314(5796):126–129.
383. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010; 116(20):4099–4102.
384. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* 2015; 348(6230):62–68.
385. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. *Nat. Rev. Cancer* 2016; 16(9):566–581.
386. Robbins PF, Lu Y-C, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat. Med.* 2013; 19(6):747–752.
387. Linnemann C, Heemskerk B, Kvistborg P et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. *Nat. Med.* 2013; 19(11):1534–1541.
388. Orentas RJ, Nordlund J, He J et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. *Front. Oncol.* 2014; 4:134.
389. Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. *Comput. Struct. Biotechnol. J.* 2016; 14:357–362.
390. Vyas M, Müller R, Pogge von Strandmann E. Antigen loss variants: catching hold of escaping foes. *Front. Immunol.* 2017; 8(175):1.
391. Kvistborg P, Shu CJ, Heemskerk B et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. *Oncoimmunology* 2012; 1(4):409–418.
392. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* 2011; 17(13):4550–4557.
393. Chapuis AG, Desmarais C, Emerson R et al. Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo. *Science Immunology* 2017; 2(8):eaal2568.
394. McCracken MN, Vatakis DN, Dixit D et al. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. *J. Clin. Invest.* 2015; 125(5):1815–1826.
395. Tavaré R, Escuin-Ordinas H, Mok S et al. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. *Cancer Res.* 2016; 76(1):73–82.
396. Mall S, Yusufi N, Wagner R et al. Immuno-PET Imaging of Engineered Human T Cells in Tumors. *Cancer Res.* 2016; 76(14):4113–4123.
397. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation

- programs to CD8+ T cells for adoptive immunotherapy. *Blood* 2008; 111(11):5326–5333.
398. Sukumar M, Liu J, Ji Y et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *J. Clin. Invest.* 2013; 123(10):4479–4488.
399. Crompton JG, Sukumar M, Roychoudhuri R et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Res.* 2015; 75(2):296–305.
400. Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. *Trends Biotechnol.* 2014; 32(9):456–465.
401. Wrzesinski C, Paulos CM, Gattinoni L et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. *J. Clin. Invest.* 2007; 117(2):492–501.
402. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* 2008; 26(32):5233–5239.
403. Goff SL, Dudley ME, Citrin DE et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. *J. Clin. Oncol.* 2016; 34(20):2389–2397.
404. Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. *Nature* 2012; 482(7385):400–404.